drugset / Trial / NCT01142336

Effects of Simvastatin on Biomarkers

NCT01142336

RandomizedParallel-groupTriple-blindPrevention

Summary

A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.

Timeline

Start
2010-06
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 40 mg

Indications